Biomarkers and Targeted Drugs for Colorectal Cancer
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: 31 August 2024 | Viewed by 115
Special Issue Editors
Interests: colorectal cancer; oncological surgery; biomarkers; cancer treatment, minimally invasive surgery; robotic surgery
Special Issue Information
Dear Colleagues,
Colorectal cancer (CRC) remains a significant health challenge worldwide, necessitating the development of innovative diagnostic and therapeutic approaches. Biomarkers have emerged as powerful tools in improving the detection, prognosis, and treatment selection for CRC.
Various types of biomarkers, including genetic, epigenetic, and protein-based markers, have demonstrated promise in detecting CRC at early stages when treatment outcomes are more favorable. The importance of biomarkers as prognostic and predictive indicators of colorectal cancer has also become increasingly prominent.
With advancements in molecular profiling techniques, targeted therapies have revolutionized cancer treatment. Targeted drugs have revolutionized the treatment of colorectal cancer, including epidermal growth factor receptor (EGFR) inhibitors, vascular endothelial growth factor (VEGF) inhibitors, and immune checkpoint inhibitors.
In conclusion, biomarkers play a critical role in the diagnosis, prognosis, and treatment of CRC. They offer the potential for early detection, risk stratification, and personalized therapies. The integration of biomarker-based strategies with targeted drugs holds great promise for further advancements in colorectal cancer therapy.
Dr. Kamil Safiejko
Dr. Maciej Dulewicz
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- colorectal cancer
- diagnosis
- biomarkers
- chemokines
- MSI
- circulating tumor cells
- circulating tumor DNA
- immunotherapy
- targeted therapies
- targeted drugs
